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Chromogranin A (CHGA) is stored and released from the
same secretory vesicles that contain catecholamines in
chromaffin cells and noradrenergic neurons. We had
previously identified common genetic variants at the CHGA
locus in several human populations. Here we focus on
whether inter-individual variants in the promoter region are
of physiological significance. A common haplotype, CGATA
(Hap-B), blunted the blood pressure response to cold stress
and the effect exhibited molecular heterosis with the greatest
blood pressure change found in Hap-A/Hap-B heterozygotes.
Homozygosity for three minor alleles with peak effects within
the haplotype predicted lower stress-induced blood pressure
changes. The G-462A variant predicted resting blood
pressure in the population with higher pressures occurring in
heterozygotes (heterosis). Using cells transfected with CHGA
promoter-luciferase reporter constructs, the Hap-B haplotype
had decreased luciferase expression compared to the TTGTC
(Hap-A) haplotype under both basal conditions and after
activation by pre-ganglionic stimuli. The G-462A variant
altered a COUP-TF transcriptional control motif. The two
alleles in transfected promoters differed in basal activity and
in the responses to COUP-II-TF transactivation and to retinoic
acid. In vitro findings of molecular heterosis were also noted
with the transfected CHGA promoter wherein the diploid
combination of the two G-462A alleles gave rise to higher
luciferase expression than either allele in isolation. Our
results suggest that common genetic variants in the CHGA
promoter may regulate heritable changes in blood pressure.
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Chromogranin A (CHGA (MIM 118910)), a 48-kDa acidic
polypeptide,1,2 is the major protein co-stored and co-released
with catecholamines from secretory vesicles in adrenal
medulla and postganglionic sympathetic axons.3 CHGA is
required for formation of catecholamine secretory vesicles in
chromaffin cells and its expression may be sufficient to
induce a regulated secretory system even in non-secretory
cells.4 CHGA is also a pro-hormone that gives rise to
biologically active peptides such as the dysglycemic peptide
pancreastatin,5,6 the antimicrobial peptide chromacin,7 the
vasodilator vasostatin,8 and catestatin that acts to inhibit
catecholamine release.9,10 Phenotypic links between CHGA
and essential (idiopathic, genetic) human11–14 and rodent15
hypertension have been repeatedly observed.16 Plasma CHGA
concentration correlates with catecholamine release rate,17
and increases in blood pressure (BP) caused by the action of
catecholamines are coupled to the formation of dense-core
secretory granules, whose biogenesis is regulated in vivo by
CHGA.18
Recently, we systematically identified common genetic
variation in human CHGA by resequencing the gene in
several human populations.19 Here, we explore whether
common interindividual genetic variation at the CHGA
promoter contributes to heritable BP variation after environ-
mental stress, an early pathogenic phenotype for later
hypertension, as well as basal BP in the population. We then
characterized the effects of an associated promoter variant on
gene expression in transfected promoter/reporter plasmids
in chromaffin cells. Our results suggest novel effects of
particular CHGA promoter variants on autonomic
circulatory control, with likely transcriptional mechanisms
identified.
RESULTS
Structure of the human CHGA locus: patterns of linkage
disequilibrium
After systematic variant discovery, we used 16 common
single-nucleotide polymorphisms (SNPs) (each with minor
allele frequency 45%), distributed across B13 kb at the
CHGA locus, to probe patterns of pairwise linkage disequili-
brium (LD) in 2n¼ 102 chromosomes (Figure 1a). The
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four-gamete algorithm20 suggested three blocks of LD across
the locus, with the most 50 block extending across the
promoter and into intron 2. Figure 1b shows the common
variants discovered in the CHGA proximal promoter.
CHGA promoter genotypes and the heritable response to
environmental stress: studies in twin pairs
CHGA promoter haplotype effects on stress traits. As
systemic hypertension may result from the cumulative effects
of transient adverse BP responses to environmental stress in
genetically predisposed individuals,21 we probed the BP
response to environmental stress, using cold as the systematic
stimulus22 in a series of predominantly normotensive twin
pairs. The stress BP traits were significantly heritable as
estimated by twin pair variance components:22 change in
diastolic blood pressure (DBP) at 32±8% (P¼ 0.0003) and
final DBP at 37±8% (Po0.0001).
We then genotyped five tightly linked common promoter
variants (at positions C–1014T, G988T, G462A, C415T,
A89C; Figure 1b), and inferred haplotypes with the HAP
algorithm.23 The three most common haplotypes, TTGTC
(Hap-A, 56.9%), CGATA (Hap-B, 23.0%), and TTGCC
(Hap-C, 16.5%), accounted for 495% of all haplotypes.
Diploid haplotypic variation in the region affected both
the change in DBP (P¼ 0.0222) and the final DBP
(P¼ 0.0167) during stress (Figure 2a). Homozygosity for
Hap-B (CGATA/CGATA) seemed to blunt both d-DBP and
final DBP, whereas Hap-A/Hap-B heterozygosity (TTGTC/
CGATA) was associated with the greatest values of both
d-DBP and final DBP (Figure 2a). The more extreme trait
values for heterozygotes (as compared to either homozygote
class) suggested the phenomenon of molecular heterosis.24
Although Hap-A and Hap-B each influenced the
stress traits (Figure 2a), Hap-3 did not demonstrate an
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Figure 1 | The human CHGA locus. (a) Patterns of linkage disequilibrium. Data are shown for 16 common (minor allele frequency
45%) biallelic polymorphisms spanning the CHGA gene, discovered by systematic resequencing with amplicons encompassing each
exon, exon/intron border, 50- and 30-UTR, and proximal promoter.19 Pairwise results are plotted on a pseudocolor scale for LD, with the
Haploview algorithm,20 for subjects self-identified as White (European ancestry, 2n¼ 102 chromosomes). LD blocks are determined by
the four-gamete rule. (b) Promoter polymorphism. Common polymorphisms in the CHGA proximal promoter are displayed in context with
other consensus promoter elements. CRE, cyclic AMP response element; UTR, untranslated region.
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independent effect, perhaps reflecting the limited statistical
power of this less common (16.5%) variant.
Individual SNP effects on the stress trait. We then analyzed
each SNP within the promoter LD block individually; the
minor alleles (in bold) at positions T–1014C, T988G, and
G462A predicted lower final/post-stress DBP
(P¼ 0.010–0.036) (Figure 2c), with the most substantial
and significant (P¼ 0.010) effect at G462A. Once again,
there was the suggestion of molecular heterosis, with G/A
heterozygotes exhibiting the highest final DBP. By Single
Nucleotide Polymorphism Spectral Decomposition
(SNPSpD),25 the experiment-wide significance threshold
required to keep the type I error rate at p5% within the
promoter haplotype block was P¼ 0.0187; this threshold was
exceeded only by G462A.
Promoter haplotype phylogeny. To explore lineages within
the trait-associated human CHGA promoter variants, we
constructed a likely phylogeny23 based on these five SNPs
genotyped in twins (Figure 2b). HAP indicated that
haplotype CGATA (Hap-B), containing the 462A allele, is
relatively ancestral within the human lineage. Hap-A
(TTGTC) is likely to be descended from another ancestral
haplotype, TTG?C, with uncertainty at position C415T.
Each allele of variant G462A is found in a likely ancestral
haplotype. Thus, both of the trait-associated haplotypes
(Hap-A, TTGTC; Hap-B, CGATA), as well as both alleles at
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Figure 2 | CHGA promoter polymorphism and autonomic control of the circulation: BP response to environmental stress.
(a) Common diploid haplotypic variation in the proximal promoter (C1014T-G988T-G462A-C415T-A89C): predicting the
BP response to environmental stress in twin pairs. Provocation of efferent sympathetic outflow was undertaken in each subject by
immersion of one hand in ice water (at 0 1C) for 1 min, with continuous BP monitoring. Results are shown for final DBP and d-DBP in 224
twins (112 twin pairs), and analyzed by generalized estimating equations, establishing an exchangeable correlation matrix to take into
account intra-twin-pair correlations. (b) Individual CHGA promoter polymorphisms predict the DBP response to environmental (cold)
stress in twin pairs. Results are shown for final DBP in twin pairs and analyzed by generalized estimating equations, establishing an
exchangeable correlation matrix to take into account intra-twin-pair correlations. (c) Haplotype phylogeny in the CHGA promoter:
T1014C-T988G-G462A-C415T-A89C. Haplotype inference23 based on genotyping data in twin pairs. The likely phylogeny
of this block is plotted. Haplotype variants A, B, and C are found in the contemporary population at the frequencies indicated.
Ancestral haplotype L is inferred rather than observed in the contemporary population (numbers in parentheses).
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G462A, are likely to be rather ancient in the human lineage.
Similar results were obtained when we estimated the
phylogeny using data across several human populations
(ancestries: European, African American, Hispanic, and east
Asian).
CHGA promoter polymorphism effects on basal BP in the
population
To probe the significance of CHGA promoter variation for
disease, we selected the variant with the peak/most significant
effect on stress BP (Figure 2b), G462A, and typed it in a
series of normotensive and hypertensive individuals
(n¼ 920) from San Diego (UCSD and VA clinics). There
were significant effects of G462A genotype on both systolic
blood pressure (SBP) (P¼ 0.030) and DBP (P¼ 0.013).
Heterozygosity (G/A genotype) predicted higher SBP and
DBP, by B3/2 mm Hg over major allele homozygotes
(Figure 3), once again suggesting molecular heterosis.24
Analysis with the covariate of ethnicity did not affect the
association results (SBP P¼ 0.028/DBP P¼ 0.011), nor did
adjustment for the effects of antihypertensive medications26
in the hypertensives (SBP P¼ 0.049/DBP P¼ 0.024).
Function of CHGA promoter variants (haplotypes and
variants)
Basal activity of transfected promoters in chromaffin cells and
corticotropes. To study the functional consequences of the
two principal trait-associated human CHGA haplotypes, we
amplified the CHGA promoter (1142/þ 54 bp) from
human samples, subcloned it into the promoter site of the
pGL3-Basic luciferase reporter vector, created necessary
variants by site-directed mutagenesis, then confirmed the
haplotypes by sequencing. We tested promoter strength by
transfection into the neuroendocrine cell lines PC12 (rat
chromaffin/pheochromocytoma cells) and AtT20 (mouse
pituitary corticotropes). In both PC12 and AtT20 cells,
haplotype TTGTC (Hap-A, containing the G462 allele)
showed higher expression of the reporter gene than Hap-B
(CGATA, with the 462A allele) (Figure 4).
Effect of secretory stimulation. We tested the reactions of
the two major haplotypes to preganglionic secretory stimuli
known to induce the transcription of CHGA: nicotinic
cholinergic agonist (nicotine), and the neuropeptides
vasoactive intestinal peptide and pituitary adenylyl
cyclase-activating polypeptide. Exposure to each of these
secretagogues augmented transcription of both haplotypes
(Hap-A, TTGTC; Hap-B, CGATA), but the TTGTC promoter
Hap-A (containing the G462 allele) displayed greater
(P¼ 0.011) responses than Hap-B (CGATA) to both nicotine
and vasoactive intestinal peptide (Figure 5).
Single-nucleotide variant effects on reporter gene activity. To
probe the effect of each variant in the promoter, we
constructed a series of haplotypes, both naturally occurring
and artificial, in which we systematically varied the base at
each variant (T–1014C, T988G, G462A, C415T,
A89C) on different backgrounds ligated to luciferase
reporters. Two-way analysis of variance then probed the
effects of each variant on basal activity in PC12 or AtT20
cells. Variants at positions T–1014C, T988G, and G462A
exerted effects on reporter gene expression in both PC12 and
AtT20 cells. Variants T415C and C89A exhibited
differential activity on gene expression: T415C principally
in PC12 cells, whereas C89A was functional mainly in
AtT20 (Figure 6).
Role of promoter variant G462A and transactivation
As G462A exhibited the peak effect on stress-induced DBP
changes in twins (Figure 2), as well as an effect (B3/
2 mm Hg) on basal BP (Figure 3), we studied its effects more
closely. Analysis of the sequence immediately surrounding
G462A (Figure 5a) by ConSite (http://www.phylofoot.org/
consite)27 revealed a partial (7/12 position, P¼ 0.0046
by Fisher’s exact test) match to a consensus COUP-TF
(chicken ovalbumin upstream promoter–transcription
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factor)28 nuclear hormone binding motif (AGGTCANAGG
TCA), consisting of two direct hexanucleotide repeats
(AGGTCA, in bold) separated by a one base spacer (‘N’).
The match improved to 8/12 for the 462A allele. Among
sequenced mammals (human, chimp, cow, rat, and mouse),
all had either G or A at the equivalent position of human
G462A; chimp and mouse displayed 6/12 base identity with
the COUP-TF motif (Figure 5a).
Basal activity. To isolate the effect of G462A as a single
independent variable, we mutated the G462 to the 462A
allele on a background of Hap-A (that is, TTGTC to TTATC),
and then transfected each haplotype into PC12 cells. Under
basal circumstances, the promoter bearing the G462 allele
was B25% more active than the 462A allele (P¼ 0.036;
Figure 5b).
COUP-II-TF stimulation. To probe the significance of the
putative COUP-TF motif (Figure 5a), we tested the effect of
COUP-II-TF by co-transfection with CHGA promoter/
reporters bearing either the G462 or the 462A allele
(Figure 5b). Each promoter variant was stimulated by COUP-
II-TF, although the increment was B8-fold greater for the
462A variant (P¼ 0.0316) that had the superior (8/12
position) COUP-TF match (Figure 5a).
Retinoic acid stimulation. The retinoid X receptor may
heterodimerize with COUP-TF,28 and retinoic acid reportedly
alters CHGA promoter activity in neurons.29 Upon retinoic
acid stimulation (Figure 5b), both G462A promoter
variants were activated, although the increment was
B2.5-fold greater for the G462 allele.
Human CHGA promoter variants in diploid combinations:
results in cella
Having observed the phenomenon of molecular heterosis
(the most extreme phenotype for the heterozygote class) in
vivo for both promoter haplotypes on stress BP increments
(Figure 2a) and G462A on basal BP in hypertension
(Figure 3), we wished to explore whether such heterosis could
also be demonstrated in an isolated cellular transfection
system (PC12 chromaffin cells).
Promoter haplotypes. We transfected luciferase-encoding
Hap-A (TTGTC)/Hap-B (CGATA) on separate plasmids in
three diploid combinations: Hap-A/Hap-A (that is, Hap-A
alone), Hap-A/Hap-B (that is, a 50:50 mixture), and Hap-B/
Hap-B. The results yielded substantial (Po0.001) differences
in luciferase expression, and reproduced the previous
findings that Hap-A was more active than Hap-B
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Figure 4 | Human CHGA promoter haplotypes (C1014T-G988T-G462A-C415T-A89C): differential activity in
chromaffin cells and corticotropes. (a) Basal activity. Transfection results for human CHGA promoter haplotype/luciferase reporters are
shown for mouse AtT20 corticotropes versus rat PC12 chromaffin cells. Results are expressed as the ratio of firefly luciferase/Renilla
luciferase (encoded by the transfection efficiency plasmid pRL-TK). Each experiment was performed in triplicate, and such experiments were
repeated at least three times. (b) Human CHGA promoter polymorphisms: site-specific effects on transcription in chromaffin cells and
corticotropes. Common variant effects on transcription of reporter gene are presented as significance (1/P-value, by analysis of variance,
with SNPs as the independent variables) in PC12 chromaffin cells and AtT20 corticotropes. (c) Human CHGA promoter haplotypes
(T–1014C-T988G-G462A-C415T-A89C): differential activity during secretory stimulation in chromaffin cells. Results are shown
as stimulated activity minus control activity (i.e., without secretagogue). Each experiment was performed in triplicate, and such experiments
were repeated at least three times. VIP, vasoactive intestinal peptide; PACAP, pituitary adenylyl cyclase-activating polypeptide.
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(Figure 4a). But in combination, the two haplotypes yielded
an apparent recessive/dominant pattern of actions of Hap-A/
Hap-B in cella (Figure 6a).
Promoter variant G462A. When the two alleles at
G462A (G462 and 462A) were isolated on the Hap-A
background (TTGTC-TTATC), fused to luciferase, and
transfected into chromaffin cells, the finding of G4A activity
was reproduced (Figure 5b), but the two alleles in combina-
tion yielded a pattern of molecular heterosis reminiscent of
the clinical effect on BP (Figure 3), in that the heterozygous
combination programmed more luciferase expression than
either of the two alleles in isolation (Figure 6b).
DISCUSSION
Overview
CHGA plays a pivotal role in the sympathochromaffin
system, both in the formation of catecholamine secretory
vesicles and in the regulation of transmitter release.1,18 In this
report, we approach the impact of common human
variations in the CHGA promoter region for autonomic
physiology and disease.
We found that common promoter variants constitute lie
within an LD block (Figure 1). A common haplotype of the
CHGA promoter region, CGATA (Hap-B; across T–1014C-
T988G-G462A-C415T-A89C), blunted the heri-
table change in BP during environmental stress in twin pairs
(Figure 2a). Homozygosity for the minor alleles at T1014C
(C/C), T988G (G/G), or G462A (A/A) was also associated
with post-stress BP in normotensive individuals (Figure 2b),
with the peak effect at G462A, suggesting a mechanism for
very early effects of these variants on a pathogenic series of
events that may eventuate in sustained/fixed basal BP
elevation (Figure 6). A/G heterozygosity at crucial variant
G462A predicted higher SBP and DBP in the population
(Figure 3).
Studies with isolated/transfected CHGA promoters
showed that common haplotype CGATA (Hap-B) exhibited
lower expression of a reporter gene, when compared to the
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Figure 5 | CHGA promoter common variant G462A. (a) Transcriptional motif prediction for the sequence surrounding CHGA G462A.
The COUP-TF motif in the sequence is shown as two direct repeats (AGGTCA) separated by a one nucleotide spacer (N). (b) Human
CHGA promoter G462A and nuclear receptor activation: effects of G462A on transcriptional activity in chromaffin cells. Allele G462
occurs naturally as part of Hap-A (TTGTC); on the Hap-A mutation background, G462 was point mutated to 462A, creating non-natural/
artificial haplotype TTATC. Results for TTGTC versus TTATC are compared with T-test. Chromaffin (PC12) cell transfection results are
shown. Left: basal activity. CHGA promoter haplotypes were transfected into PC12 cells without stimulation (‘mock’). Basal activity results are
presented as firefly luciferase activity normalized to cell protein. Middle: COUP-II-TF expression. COUP-II-TF (in cytomegalovirus
promoter expression plasmid pCR3.1; Invitrogen) was co-transfected at 50 ng. The control transfection was performed with the empty
vector pCR3.1. Results are presented as net activity (stimulation minus basal, for each haplotype). Right: retinoic acid stimulation. Results
are presented as net activity (stimulation minus basal, for each haplotype), where stimulation was 1 mM retinoic acid.
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most common haplotype, TTGTC (Hap-A) (Figure 4).
Under stimulation by triggers to chromaffin cell exocytosis
(Figure 4c), such as nicotine and vasoactive intestinal
peptide, both promoter haplotypes were activated, but the
increase was blunted in CGATA (Hap-B) compared with
TTGTC (Hap-A). Crucial SNP G462A affected a consensus
nuclear receptor transcriptional motif for COUP-TF (Figure
5a), and when created by site-directed mutagenesis, this
variant affected not only basal expression but also the
response to COUP-II-TF or to retinoic acid (Figure 5b).
These results suggest a mechanistic chain of events (Figure 6)
whereby common CHGA promoter variant G462A plays a
role in the determination of human BP.
Intermediate phenotypes
Essential hypertension is a complex trait,30 with multiple
contributory factors derived from both genes and environ-
ment. In the setting of late penetrance of the ultimate disease
trait (such as hypertension), as well as likely genetic
heterogeneity, the ‘intermediate phenotype’31 strategy may
be a useful approach in the search for disease predisposition
loci. Autonomic traits with heritable determination may be of
particular value in investigation of the genetic underpinnings
of hypertension. In accordance with this pathway concept, we
pursued intermediate traits in this study. The hemodynamic
response to environmental (cold) stress may be a predictor of
the development of later cardiovascular events, such as
hypertension.32–36 Such a response, occurring even before the
onset of disease, would be a useful physiological intermediate
phenotype in probing the genetic determinants of hyperten-
sion.16,31,37 We report the cold stress response in our twins,
indicating that both change in DBP and final (post-stress)
DBP are heritable.22
Molecular heterosis
CHGA promoter Hap-A (TTGTC) and Hap-B (CGATA), the
two most common promoter haplotypes, influenced the BP
response to environmental stress (Figure 2a), with Hap-B
homozygosity (CGATA/CGATA) predicting both lower
change and final BP after stress (Figure 2a). The peak effect
for this process was noted for position G462A (Figure 2b).
Both the haplotype (Figure 2a) and individual SNP (Figure
2b) effects were more extreme for heterozygotes, suggesting
‘molecular heterosis’,24 a phenomenon also observed for the
effect of G462A on basal/resting BP in the population
(Figure 3).
The phenomenon of molecular heterosis has been defined
as occurring when polymorphism at a single genetic locus
displays a significantly greater or lesser effect on a
quantitative trait than homozygosity at the same locus.24
Although the phenomenon may initially seem counter-
intuitive, it may be explained by one of several underlying
mechanisms, including a U-shaped dose–response relation-
ship for gene on trait, greater ‘fitness’ in heterozygotes, or
hidden stratification in one homozygote class. One such
stratification might be the effect of allelic variation at other
(non-CHGA) trans-Quantitative Trait Loci (QTLs) on cold
stress and basal BPs, such as the associations we have
reported for polymorphisms at tyrosine hydroxylase22,24 or
rho kinase.38
We also observed that heterozygous diploid combinations
of G462A (Figure 6b) created a more extreme phenotype
(in this case, luciferase expression) than either homozygote
class. Thus, the phenomenon of molecular heterosis at
G462A seems not to require systemic influences, or even
effects of hidden stratification at other loci, as PC12 is a
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Figure 6 | Human CHGA promoter variants in diploid
combinations in cella: transfection of CHGA promoter/
luciferase reporter plasmids into PC12 chromaffin cells.
(a) Haplotype combinations: apparent recessive/dominant actions
of Hap-A/Hap-B in cella. Hap-A (TTGTC) and Hap-B (CGATA), each
fused to the luciferase reporter, were transfected in three diploid
combinations: Hap-A/Hap-A (1000 ng of Hap-A alone, to test
Hap-A homozygosity), Hap-A (500 ng)/Hap-B (500 ng) (to test
heterozygosity), or Hap-B/Hap-B (1000 ng of Hap-B alone, to test
Hap-B homozygosity). (b) G462A combinations: evidence for
molecular heterosis in cella. The parent haplotype was Hap-A
(TTGTC) fused to luciferase, onto which the 462A variant was
introduced by site-directed mutagenesis, yielding TTATC. Three
diploid combinations were transfected: G/G (TTGTC alone, to test
homozygosity, 1000 ng), G/A (TTGTC/TTATC, to test
heterozygosity, 500 ng/500 ng), or A/A (TTATC alone, to test
homozygosity, 1000 ng).
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clonal chromaffin cell line.39 Perhaps a clue to the origin of
molecular heterosis in this setting lies in the motif harboring
G462A (Figure 5a): the nuclear receptor COUP typically
forms heterodimers with other members of that transcription
factor subfamily (such as the retinoid X receptor), creating
the possibility of interactive (that is, non-additive) effects.
Indeed, the retinoid receptor ligand retinoic acid differen-
tially activated the G462 and 462A alleles in the
transfected CHGA promoter (Figure 5b, right).
Regardless of mechanism, the phenomenon of molecular
heterosis points out the value of trait associations with
diploid genotypes rather than simply with alleles, which
could not capture such effects.24
Biological role of promoter haplotypes and G462A
Our results suggest that a discrete variant in the CHGA
promoter (G462A) may play a role in control of BP, with
sequential effects (Figure 7) beginning at transcriptional
control (Figures 4 and 5), proceeding through an inter-
mediate/risk phenotype (Figure 2), and eventuating in basal
BP changes in the population (Figure 3). Both hypertensive
patients and subjects with still-normal BP (but at genetic risk
of hypertension) may display derangements of autonomic
function, including changes in CHGA expression.3,12 As
CHGA is crucial in the formation of catecholamine secretory
vesicles as well as the regulation of transmitter release,1,18
transcriptional control of CHGA may thus be an early control
point in development of cardiovascular risk.
Previously, we found that the proximal promoter region of
CHGA governs its transcription, under both basal circum-
stances and secretory stimulation, consistent with the notion
of ‘stimulus–secretion–synthesis coupling,’ or ‘stimulus–tran-
scription coupling.’40–44 The cyclic AMP response element
site in the very proximal CHGA promoter (human CHGA
promoter 50-T-51GACGTCA-44-30) was identified to be crucial
in neuroendocrine-specific expression of CHGA45,46 and its
response to secretory stimulation.40–42 When we undertook
systematic polymorphism discovery at human CHGA,19 the
cyclic AMP response element box was devoid of variation,
but we did discover 13 single-nucleotide variants within the
first B1.2 kb of the CHGA promoter, with minor allele
frequencies up to B29%; indeed, the abundance of
heterozygosity at the CHGA promoter suggested a signature
for positive (perhaps ‘balancing’) selection.19
As the two most common CHGA promoter haplotypes,
TTGTC and CGATA, showed differential effects on post-
stress BP (Figure 2), we attempted to understand how these
two haplotypes influence gene expression. Hap-A (TTGTC)
showed higher expression of the reporter gene than Hap-B
(CGATA), under not only basal (Figure 4a) but also
secretion–stimulatory conditions (Figure 4c). Nicotine con-
sumption has been identified as a risk factor for cardio-
vascular diseases, such as hypertension.47 The transcription
of CHGA is activated by nicotinic stimulation, and the
response seems to map onto the proximal promoter.40,42
Greater reactivity of Hap-A (TTGTC) to both stress in vivo
(Figure 2a) and secretory stimulation in cultured chromaffin
cells (Figure 4) suggests that augmented transcription of this
common haplotype may play a role in human stress
responses that are precursors to adverse cardiovascular
outcomes, such as hypertension.40,42
Among the five common variants (T1014C-
T988G-G462A-C415T-A89C) used to probe
the CHGA promoter haplotype block, G462A yielded the
peak prediction of post-stress BP (Figure 2b), as well as BP in
the population (Figure 3).
As this variant modified a known transcriptional control
motif (Figure 5a), we explored the effect of this variant in
transfected promoters. First, we created the variant, by site-
directed mutagenesis (G-A) on the Hap-A background
(that is, TTGTC-TTATC). Then, we tested the effect of this
variant on transfected promoter/reporter gene expression in
chromaffin cells, under basal circumstances as well as during
perturbation by co-transfected/expressed COUP-II-TF or
retinoic acid (selected as COUP may heterodimerize with
other nuclear hormone receptors, such as the retinoid X
receptor).28 In each case, the G462A purine-purine
transition altered transcriptional efficiency of the promoter
(Figure 5b).
The COUP-TF is an ‘orphan’ (that is, endogenous ligand
unknown) within the nuclear receptor family.28 Two loci,
COUP-TFI (also termed EAR3) and COUP-TFII (also termed
ARP-1), have been identified in mammals. These are closely
related transcription factors that are widely expressed and
involved in the regulation of several biological processes.28
COUP-TFs are generally considered to be repressors of
transcription for other nuclear hormone receptors;28,48,49
however, COUP-TFs can also activate an ever-growing list of
gene promoters.50 COUP-TFs can exist in solution as either
homo- or heterodimers, binding with high affinity to an
imperfect (GTGTCANAGGTCA, or ‘DR1’) or perfect
(AGGTCANAGGTCA) direct hexanucleotide repeat (in bold
type) separated by a one nucleotide ‘spacer’ (or N).51,52
COUP-TFs may also bind to a number of variably spaced
direct hexanucleotide repeats.51,52 Here, we found that
COUP-II-TF exerted quite different effects on the G and A
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Figure 7 | Intermediate phenotype hypothesis for the
cardiovascular consequences of CHGA promoter genetic
variation. Framework hypothesis for the effects of CHGA
promoter variant G462A on intermediate traits, and ultimately
on BP in the population.
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alleles (Figure 5b, center), with the A response exaggerated,
perhaps expected in that the A allele provides a better
COUP-TF consensus match (Figure 5a).
The basal expression pattern of G462A was G4A
(Figure 5b, left), whereas the COUP-activated pattern was
A4G (Figure 5b, center), suggesting that COUP alone might
not account for differences in basal expression of the G462
versus 462A alleles. We thus turned to other potential
transactivators of G462A. To activate potential COUP-TF/
retinoid X receptor heterodimers, we treated the transfected
promoters with retinoic acid, a stimulus known to affect
CHGA expression;29 once again, the G and A alleles
responded differently, this time with a greater response by
the G variant (G4A; Figure 5b, right). The response to
retinoic acid mirrored the basal promoter differences (in each
case, G4A; Figure 5b, left and right panels), suggesting that
the basal expression differences (G4A) might in part be
mediated by retinoids.
Conclusion and perspectives
We began with an analysis of common haplotypes in the
CHGA promoter, and first established an early, potentially
pathogenic effect on autonomic control of the circulation.
The effect was maximal for promoter variant G462A, which
also exhibited an effect on resting/basal BP in the population.
Common promoter haplotypes differed in transcriptional
strength in transfected promoter/reporter constructs. The
G462A site altered a consensus COUP-TF transcriptional
motif, and site-directed mutagenesis of the site altered not
only basal transcription but also the response to COUP-II-TF
or retinoic acid. The findings are consistent with a cascade of
events (Figure 7), beginning with the G462A variant and
eventuating in altered BP. The results suggest new approaches
to the pathogenesis, prediction, and management of
disorders of autonomic circulatory control.
MATERIALS AND METHODS
Molecular genetics
Genomic DNA was prepared from leukocytes in EDTA-antic-
oagulated blood, using PureGene extraction columns (Gentra
Biosystems, Minneapolis, MN, USA) as described.53
Genotyping. SNP diploid genotypes were scored by either of
two base-extension systems: the MALDI-TOF system of Sequenom
(La Jolla, CA, USA)54 or the luminescent system of Pyrosequencing
(Uppsala, Sweden).55 In each case, initial PCR amplification of the
template was followed by primer-mediated base extension across the
variant position. Pyrosequencing primers were designed using the
dedicated software provided by Pyrosequencing. Target sequences
were amplified by PCR from 15 ng genomic DNA in a final volume
of 10 ml. To ensure accurate assignment, genotypes were verified by
visual inspection and artifactual data were excluded from further
statistical analysis. CHGA SNP genotype call rates in the twins (with
the Hardy–Weinberg equilibrium, w2 and P-values) were as follows:
C1014T, 97.9% (w2¼ 10.98, P¼ 0.001); G988T, 98.1%
(w2¼ 0.755, P¼ 0.385); G462A, 92.8% (w2¼ 0.699, P¼ 0.403);
C415T, 90.0% (w2¼ 1.77, P¼ 0.183); and A89C, 97.2%
(w2¼ 0.359, P¼ 0.549). As C1014T deviated from the
Hardy–Weinberg equilibrium, we also imputed promoter haplotypes
(see below) with and without this SNP, but the individual haplotype
assignments did not change.
Polymorphism discovery across the CHGA locus. Human
reference genome sequence was obtained from the University of
California Santa Cruz (UCSC) Genome Browser (http://genome.
ucsc.edu). We resequenced the CHGA locus (eight exons, intron/
exon borders, untranslated regions, and proximal promoter) for
systematic variant discovery in n¼ 180 subjects (2n¼ 360 chromo-
somes) of diverse ancestries, as previously described.19
Subjects and clinical characterization
Twin pairs. Twin subject characteristics are described in our
previous reports,22 and each subject gave written informed consent
to the protocol approved by the local institutional review board.
Twin pairs, aged 15–84 years (median, 40 years), were 69%
monozygotic and 31% dizygotic. Twin zygosity was confirmed by
single-nucleotide and microsatellite polymorphisms, as previously
described.38,56,57 A total of 9.9% of the twins are hypertensive (8.8%
treated with antihypertensive medications). Twin phenotyping is
described below.
Environmental (cold) stress in twin pairs. A total of 112 (N)
twin pairs (2n¼ 224 individuals) were studied. For marker-on-trait
analyses, each subject was self-identified as being of white
(European) ancestry, as were both parents and all four grandparents.
BP and heart rate were recorded continuously and non-invasively
with a calibrated radial artery applanation device and dedicated
sensor hardware (Colin Pilot; Colin Instruments, San Antonio, TX,
USA) and software (ATLAS, WR Medical, Stillwater, MN, USA;
TDA (Tonometric Data Analysis), Colin Instruments) during the
CPT (cold pressor test; immersion of the left hand in ice water for
60 s, after a 10-min rest), as previously described.16,22 Heart rate was
similarly recorded with thoracic EKG electrodes. We identified at
least three beats with consistent (within ±10%) values for BP and
heart rate just before and at the end of the CPT, and resulting
changes in BP and heart rate were recorded after 1 min of cold
exposure.
Hypertension sample. A case–control study was performed in a
University of California, San Diego (UCSD and VA clinics) sample
of 920 individuals, of whom 22% (n¼ 204 cases) were diagnosed
with essential hypertension, whereas 78% (n¼ 715 controls) were
normotensive. BP was obtained in seated individuals by brachial
oscillometric cuff, and triplicate values were averaged. These
individuals were 49.4% (n¼ 454) male and 50.6% (n¼ 465) female,
and aged 42.9±0.5 (range: 15–89) years. Hypertensive subjects with
evidence of secondary hypertension (on physical examination or
screening laboratory tests) were excluded; renal function was normal
(serum creatinine p1.5 mg per 100 ml) in all individuals. BP values
were age- and sex-adjusted for genetic analyses. All individuals were
self-identified as of white race, with 90.5% identified as solely of
European ancestry and 9.5% with Mexican ancestry. Diploid
genotype frequencies at CHGA G462A did not differ by ancestry
(w2¼ 4.48, P¼ 0.106), and ethnicity as a covariate did not affect the
marker-on-trait analysis for hypertension. Seventy-two percent of
the hypertensives were treated with one or more antihypertensive
medications (including angiotensin-converting enzyme inhibitors,
b-adrenergic antagonists, and diuretics); marker-on-trait analysis
results were not affected by medication adjustment of BP
values using the algorithm of Cui et al.26 SBP (at 143.6±1.3 versus
126.5±0.6 mm Hg, Po0.001), DBP (at 79.0±0.8 versus
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70.8±0.4 mm Hg, Po0.001), and body mass index (at 28.5±0.4
versus 25.6±0.2 kg m2, Po0.001) were elevated in the subjects
with hypertension.
Function of CHGA promoter variants
Cell culture. Neuroendocrine cell lines were the rat adrenal
medullary chromaffin cell line PC1239 and the mouse anterior
pituitary corticotrope cell line AtT20.58 Cell lines were grown in
high-glucose Dulbecco’s modification of Eagle’s medium with
penicillin G (100 U ml1) and streptomycin sulfate (100 mg ml1).
The medium for AtT20 cells was supplemented with 10% fetal
bovine serum. The medium for PC12 cells was supplemented with
10% horse serum and 5% fetal bovine serum.
Promoter/luciferase reporter plasmids. Human CHGA pro-
moter/reporter plasmids were constructed essentially as previously
described.19,46,59 Haplotype-specific promoter fragments corre-
sponding to CHGA 1142/þ 54 bp (/þ with respect to the cap
site) were amplified from genomic DNA of known homozygotes (or
heterozygotes for the two least common haplotypes), and subcloned
into the upstream promoter site of the pGL3-Basic vector (Promega
Inc., Madison, WI, USA). Synthetic replacements were made by site-
directed mutagenesis (Quik-Change; Stratagene, La Jolla, CA, USA).
All promoter fragments were sequence-verified before use. Promoter
positions are numbered upstream () or downstream (þ ) of the
cap site. Plasmids were purified on columns (Qiagen, Valencia, CA,
USA) before transfection.
Transfection and reporter assay. Cell lines were transfected
(at 50–60% confluence, 1 day after 1:4 splitting) with 1 mg of the
constructs mentioned above and 10 ng of the Renilla luciferase
expression plasmid pRL-TK (Promega Inc.), as an internal control
per well, by the liposome method (Superfect; Qiagen). The firefly
and Renilla luciferase activities in the cell lysates were measured 18 h
after transfection, and the results were expressed as the ratio of
firefly/Renilla luciferase activity (Stop & Glo; Promega Inc.). Each
experiment was repeated a minimum of three times.
Secretory or transcriptional stimulation. Human CHGA
promoter/reporter plasmids were transfected into PC12 cells as
described above, and the secretory stimuli nicotine (1 mM),
vasoactive intestinal peptide (1mM), or pituitary adenylyl cyclase-
activating polypeptide (0.2 mM) were added to the medium. The
firefly luciferase activities in the cell lysates were measured 18 h after
transfection, and the results were expressed as the ratio of firefly
luciferase activity/cell lysate protein. Retinoic acid (1 mM) was added
to PC12 cell cultures after transfection of CHGA promoter vectors.
The firefly luciferase activities in the cell lysates were measured 24 h
after transfection, and the results were expressed as the ratio of
firefly luciferase activity/cell protein. A 50 ng portion of a COUP-
TFII (ARP-1)60 expression plasmid (in the cytomegalovirus
promoter vector pCR3.1; Invitrogen, Carlsbad, CA, USA) or the
insert-less control vector (pCR3.1) were co-transfected with the
CHGA promoter/reporter plasmid (1mg) into PC12 cells. The firefly
luciferase activities in the cell lysates were measured 18 h after
transfection, and the results were expressed as the ratio of firefly
luciferase activity/cell protein. The transactivator plasmids were the
gift from Nathanael J Spann, UCSD.
Statistical analyses
Pairwise LD between each common SNP pair across the CHGA
locus was visualized by Haploview.20 We selected promoter SNPs for
analysis based upon the 50 haplotype block at CHGA (Figure 1),
focusing on the core of that block within the proximal promoter
(SNPs 3–7; C1014T, G988T, G462A, C415T, and A89C)
with especially high LD between SNPs 3 (T1014C) and 7
(C89A). HAP (version 3.0) was used to impute promoter
haplotypes from diploid genotype data at these five individual
SNP loci in twins.23 Haplotype assignments were conducted with all
twin individuals included or with just one twin per pair; the results
were identical.
Descriptive statistics (mean±s.e.m.) were computed for geno-
type groups across both members of each twin pair, using
generalized estimating equations, in SAS (Statistical Analysis
System, Cary, NC, USA), establishing an exchangeable correlation
matrix to take into account intra-twin-pair correlations.61 Data were
stored in Microsoft Access, and analyses were conducted in SPSS
(Statistical Package for the Social Sciences, Chicago, IL, USA; for the
BP association study), SAS, or SOLAR (for trait heritability). If traits
were not normally distributed, values were log10-transformed to
decrease skewness. One-way post hoc analysis of variance with
Bonferroni correction and T-tests were performed to evaluate the
effects of particular promoter SNPs during in vitro reporter gene
expression activity. To safeguard against the consequences of
multiple comparisons when testing the effect of five CHGA SNPs
in the promoter haplotype block on autonomic traits, we used the
method of SNPSpD proposed by Nyholt25 and available at http://
genepi.qimr.edu.au/general/daleN/SNPSpD/ to yield an ‘effective’
number of markers within a block of linkage disequilibrium. For
this purpose, we used CHGA promoter SNP data from one member
of each twinship (that is, one founder per family). This method
takes into account intermarker correlations in calculating a new
experiment-wide threshold to keep the type I error rate at p5%.
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